0001209191-23-050222.txt : 20230920
0001209191-23-050222.hdr.sgml : 20230920
20230920200824
ACCESSION NUMBER: 0001209191-23-050222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230918
FILED AS OF DATE: 20230920
DATE AS OF CHANGE: 20230920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHESS ROBERT
CENTRAL INDEX KEY: 0001227886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 231267578
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-18
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001227886
CHESS ROBERT
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
1
0
0
0
1
Common Stock
2022-09-22
4
S
0
10200
0.67
D
274773
D
Common Stock
2100
I
by daughter
Common Stock
2100
I
by son
Common Stock
2100
I
by daughter
Stock Option
0.68
2023-09-19
4
A
0
85000
0.00
A
2031-09-18
Common Stock
85000
85000
D
This transaction was made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Includes 56,794 shares previously reported as shares held in Grantor Retained Annuity Trusts for which the reporting person was the sole trustee.
The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023.
Mark A. Wilson, Attorney-in-Fact
2023-09-20